Valuation: InspireMD Inc

Market Cap 30.45M 26.35M 24.54M 22.55M 42.65M 2.9B 43.21M 290M 113M 1.45B 114M 112M 4.78B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 30.45M 26.35M 24.54M 22.55M 42.65M 2.9B 43.21M 290M 113M 1.45B 114M 112M 4.78B EV / Sales 2026 *
2.93x
EV / Sales 2027 * 1.39x
Free-Float
80.17%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 01/01/2020
Director of Finance/CFO 58 25/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 02/06/2017
Director/Board Member 68 07/02/2013
Director/Board Member 62 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-6.42%-1.38%-13.79%+16.63% 125B
-2.48%+1.62%+0.17%-1.53% 13.12B
-1.07%+8.56%+93.50%+117.37% 9.83B
+1.11%+10.55%-40.93%-66.58% 4.86B
-2.28%-0.67%-3.31%+33.83% 2.61B
-0.51%+7.84%+13.25%-54.26% 1.68B
+1.24%+5.88%-24.84%-31.18% 1.68B
+0.60%+5.00%-14.81%-19.18% 1.67B
Average -1.23%+3.05%+1.15%-0.61% 20.05B
Weighted average by Cap. -5.26%-0.18%-6.57%+17.46%

Financials

2026 *2027 *
Net sales 10.38M 8.98M 8.36M 7.68M 14.53M 990M 14.73M 98.66M 38.65M 493M 38.96M 38.11M 1.63B 21.92M 18.97M 17.66M 16.23M 30.7M 2.09B 31.1M 208M 81.65M 1.04B 82.3M 80.49M 3.44B
Net income - -
Net Debt - -
Logo InspireMD Inc
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Employees
-